Allogene Therapeutics Expands ALPHA3 Study to South Korea and Australia
Allogene Therapeutics announced that regulatory authorities in South Korea and Australia have cleared the Company to expand its pivotal Phase 2 ALPHA3 study evaluating cemacabtagene ansegedleucel in first-line consolidation treatment for patients with large B-cell lymphoma, LBCL. The study, currently enrolling across more than 60 sites in North America, will expand to over 80 global sites with the addition of South Korea and Australia. This growing trial footprint reflects strong interest in ALPHA3 from clinical trial sites. "Expanding into South Korea and Australia allows us to leverage regions with established clinical research infrastructure and experienced investigators," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "These countries provide high-quality trial environments and efficient healthcare delivery systems. These regulatory approvals, follow our recent interim futility analysis, and we expect this expansion to support the continued enrollment and global development of cema-cel."
